Off-label drug use in palliative medicine: Delphi study for the consensus of evidence-based treatment recommendations

被引：0
作者：
Puegge, Stefanie [1 ]
Dukic-Ott, Aleksandra [1 ]
Baumgaertel, Julian [1 ]
Juenger, Saskia [2 ]
Bausewein, Claudia [1 ]
Remi, Constanze [1 ]
机构：
[1] Ludwig Maximilians Univ Munchen, LMU Univ Hosp, Dept Palliat Med, Marchioninistr 15, D-81377 Munich, Germany
[2] Hsch Bochum, Dept Hlth Sci, Bochum, Germany
来源：
PALLIATIVE MEDICINE | 2025年
关键词：
Off-label use; palliative medicine; Delphi technique; patient safety; drug information services; SECTIONAL NATIONAL-SURVEY; CARE; ONCOLOGY; QUALITY;
D O I：
10.1177/02692163251323123
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
Background: Off-label use of drugs is an integral part of everyday clinical practice in palliative medicine. However, it is associated with many uncertainties, that is, drug therapy safety or legal issues including cost coverage. Healthcare professionals often lack time and resources for comprehensive literature search and patient-specific risk-benefit analyses.Aim: The aim of this project is to develop, evaluate and rate agreement/disagreement on treatment recommendations for off-label use in adult palliative medicine.Design: Online Delphi study with two rounds each to rate agreement/disagreement with treatment recommendations for off-label use in adult palliative medicine. An international expert panel consisting of physicians, pharmacists and nurses working in palliative care evaluated previously developed recommendations based on the best available evidence.Setting:/participants: Professionals (physicians, pharmacists, nursing staff) working in inpatient and home palliative care involved in the medication process were recruited as experts to participate. Between 64 and 75 experts participated in the first two Delphi studies.Results: A total of 64/68 recommendations on 21 drugs and 14 applications were agreed upon. Topics related to routes of administration as well as indications for sialorrhea, bronchorrhea, xerostomia, pruritus, singultus, fistula, gastroparesis and hot flashes. Recommendations that reached consensus are available to health care professionals via a free of charge database.Conclusion: For many off-label use applications, it is likely that there will be no registration studies and therefore no drug approvals in the future. The consensus-based recommendations are intended to facilitate individual treatment planning for prescribers and to enable a more reflected handling of off-label use.
引用
收藏
页码：530 / 542
页数：13
相关论文
共 45 条
  • [1] Guideline on good pharmacovigilance practices (GVP) Annex I – definitions (Rev 4), (2017)
  • [2] Balan S., Hassali M.A.A., Mak V.S.L., Two decades of off-label prescribing in children: a literature review, World J Pediatr, 14, pp. 528-540, (2018)
  • [3] Allen H.C., Garbe M.C., Lees J., Et al., Off-Label medication use in children, more common than we think: a systematic review of the literature, J Okla State Med Assoc, 111, pp. 776-783, (2018)
  • [4] Garcia-Lopez I., Cuervas-Mons Vendrell M., Martin Romero I., Et al., Off-Label and unlicensed drugs in pediatric palliative care: a prospective observational study, J Pain Symptom Manage, 60, pp. 923-932, (2020)
  • [5] Saiyed M., Ong P., Chew L., Off-label drug use in oncology: a systematic review of literature, J Clin Pharm Ther, 42, pp. 251-258, (2017)
  • [6] Zarkavelis G., Amylidi A.L., Verbaanderd C., Et al., Off-label despite high-level evidence: a clinical practice review of commonly used off-patent cancer medicines, ESMO Open, 8, (2023)
  • [7] Hagemann V., Bausewein C., Remi C., Off-label-prescriptions in daily clinical practice – a cross-sectional national survey of palliative medicine physicians, Prog Palliat Care, 27, pp. 154-159, (2019)
  • [8] To T.H., Agar M., Shelby-James T., Et al., Off-label prescribing in palliative care – a cross-sectional national survey of palliative medicine doctors, Palliat Med, 27, pp. 320-328, (2013)
  • [9] Kwon J.H., Kim M.J., Bruera S., Et al., Off-Label medication use in the inpatient palliative care unit, J Pain Symptom Manage, 54, pp. 46-54, (2017)
  • [10] Wittich C.M., Burkle C.M., Lanier W.L., Ten common questions (and their answers) about off-label drug use, Mayo Clin Proc, 87, pp. 982-990, (2012)
12345